Healthcare Industry News:  Microcyn 

Biopharmaceuticals Dermatology Regulatory

 News Release - January 14, 2016

Oculus Innovative Sciences Receives European CE Mark for New MucoClyns(TM) for First Responders

PETALUMA, Calif., Jan. 14, 2016 -- (Healthcare Sales & Marketing Network) -- Oculus Innovative Sciences, Inc. (OCLS), warrants OCLSW, a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of a new CE Mark in Europe for Microcyn-based MucoClyns™, a Microcyn-based solution intended for use in emergencies. It is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces for treatment immediately after an unexpected exposure to infection risk, and before receiving professional medical attention.

“Oculus has a strong commitment to helping military personnel, fire department, police officers and all of the brave men and women called into action as first responders to safely handle unexpected infection risks, both to their patients and themselves in emergency settings,” said Lori Smith, senior vice president of marketing and sales for Oculus. “MucoClyns is an easy-to-use one-step solution that helps to prevent infection and provide first responders with a clinically proven formulation that can be used in all situations since it is as safe as saline and non-flammable.”

Oculus is currently in discussions with potential European partners for the distribution of MucoClyns in Europe. Future consumer applications for the general population are also being evaluated.

About Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “discussions,” “evaluated,” and “provide,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s common stock and warrants may be delisted from NASDAQ, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the year ended March 30, 2015. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Oculus®, Microcyn® Technology and MucoClyns™ are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Source: Oculus Innovative Sciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.